KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to -$7.6 million.

  • Recursion Pharmaceuticals' Gains from Investment Securities rose 141.76% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.9 million, marking a year-over-year decrease of 286.57%. This contributed to the annual value of -$7.6 million for FY2024, which is 123.86% down from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Gains from Investment Securities is -$7.6 million, which was down 123.86% from -$3.4 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Gains from Investment Securities registered a high of -$781,000 during FY2020, and its lowest value of -$7.6 million during FY2024.
  • For the 3-year period, Recursion Pharmaceuticals' Gains from Investment Securities averaged around -$3.9 million, with its median value being -$3.4 million (2023).
  • In the last 5 years, Recursion Pharmaceuticals' Gains from Investment Securities crashed by 424.58% in 2021 and then surged by 79.74% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Gains from Investment Securities (Yearly) stood at -$781,000 in 2020, then crashed by 424.58% to -$4.1 million in 2021, then skyrocketed by 79.74% to -$830,000 in 2022, then plummeted by 308.07% to -$3.4 million in 2023, then plummeted by 123.86% to -$7.6 million in 2024.